

Information on Licensed Influenza Vaccine by Age Group, 2013-14 Influenza Season*

Vaccine	Trade name	Manufacturer	Age group	No. of doses	Presentation	Route
Trivalent Inactivated Vaccine	Flucelvax®	Novartis Vaccines	≥18 yrs	1	0.5 mL prefilled syringe	Intramuscular§
	Fluvirin®	Novartis Vaccines	≥4 yrs	1 or 2†	0.5 mL prefilled syringe	Intramuscular§
					5.0 mL multi-dose vial	
	Fluarix®	GlaxoSmithKline	≥3 yrs	1 or 2†	0.5 mL prefilled syringe	Intramuscular§
	FluLaval®	ID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline)	≥3 yrs	1 or 2†	5.0 mL multi-dose vial	Intramuscular§
	Afluria®	CSL Biotherapies (distributed by Merck)	≥9 yrs**	1	0.5 mL prefilled syringe	Intramuscular§
					5.0 mL multi-dose vial	
	Fluzone®	Sanofi Pasteur	6-35 mos	1 or 2†	0.25 mL prefilled syringe	Intramuscular§
			≥36 mos	1 or 2†	0.5 mL prefilled syringe	
			≥36 mos	1 or 2†	0.5 mL single-dose vial	
≥6 mos			1 or 2†	5.0 mL multi-dose vial		
Fluzone®—Intradermal	Sanofi Pasteur	18-64 yrs	1	0.1 mL prefilled microinjection system	Intradermal	
Trivalent Inactivated Vaccine High-Dose††	Fluzone® High-Dose	Sanofi Pasteur	≥65 yrs	1	0.5 mL prefilled syringe	Intramuscular§
Quadrivalent Inactivated Vaccine	Fluarix®	GlaxoSmithKline	≥3 yrs	1 or 2†	0.5 mL prefilled syringe	Intramuscular§
	FluLaval®	ID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline)	≥3 yrs	1 or 2†	5.0 mL multidose vial	Intramuscular§
	Fluzone®	Sanofi Pasteur	6-35 mos	1 or 2†	0.25 mL prefilled syringe	Intramuscular§
			≥36 mos	1 or 2†	0.5 mL prefilled syringe	Intramuscular§
≥36 mos			1 or 2†	0.5 mL single-dose vial	Intramuscular§	
Trivalent Recombinant Vaccine	FluBlok®	Protein Sciences	18-49 yrs	1	0.5 mL single-dose vial	Intramuscular§
Live Attenuated Influenza Vaccine, Quadrivalent	FluMist® §§	MedImmune	2-49 yrs***	1 or 2†	0.2 mL prefilled intranasal sprayer	Intranasal

Continued on other side

Adapted from:

Centers for Disease Control and Prevention Website: <http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm#table1> accessed September 9, 2013



Acute Disease Service

Oklahoma State Department of Health

For further information call or visit us on the World Wide Web
 Acute Disease Service
 Oklahoma State Department of Health
 Phone (405) 271-4060

Immunization providers should check Food and Drug Administration--approved prescribing information for 2013--14 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, and precautions. Package inserts for US-licensed vaccines are available at <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm>.

§ For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh.

† To determine the number of doses needed for children aged 6 months through 8 years refer to Figure 1: <http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm#figure1>

** Age indication per package insert is ≥ 5 years; however, refer to the Advisory Committee on Immunization Practices recommendations regarding age.

†† Trivalent Inactivated Vaccine high-dose: A 0.5-mL dose contains 60 μ g each of A/California/7/2009 (H1N1)-like, A/Victoria/361/2011 (H3N2)-like, and B/Wisconsin/1/2010-like (Yamagata lineage) antigens.

*** FluMist is indicated for healthy, nonpregnant persons aged 2--49 years. Individuals who care for severely immunosuppressed persons who require a protective environment should not receive FluMist given the theoretical risk of transmission of the live attenuated vaccine virus.

§§ It is anticipated that the quadrivalent formulation of FluMist® will replace the trivalent formulation for the 2013-14 season. FluMist® is shipped refrigerated and stored in the refrigerator at 35°F--46°F (2°C--8°C) after arrival in the vaccination clinic. The dose is 0.2 mL divided equally between each nostril. Health-care providers should consult the medical record, when available, to identify children aged 2--4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV, parents or caregivers of children aged 2--4 years should be asked: "In the past 12 months, has a health-care provider ever told you that your child had wheezing or asthma?" Children whose parents or caregivers answer "yes" to this question and children who have asthma or who had a wheezing episode noted in the medical record within the past 12 months should not receive FluMist®.

Adapted from:

Centers for Disease Control and Prevention Website: <http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm#table1> accessed September 9, 2013



Acute Disease Service
Oklahoma State
Department of Health

For further information call or visit us on the World Wide Web
Acute Disease Service
Oklahoma State Department of Health
Phone (405) 271-4060